Roth Capital Has Bearish Estimate for Accuray Q2 Earnings

Accuray Incorporated (NASDAQ:ARAY) – Stock analysts at Roth Capital lowered their Q2 2025 earnings per share estimates for Accuray in a research note issued to investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.05 EPS.

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Trading Down 0.5 %

NASDAQ ARAY opened at $1.83 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. Accuray has a twelve month low of $1.40 and a twelve month high of $3.05. The firm has a market capitalization of $184.03 million, a PE ratio of -10.76 and a beta of 1.40. The stock’s 50 day moving average is $1.85 and its 200 day moving average is $1.83.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The company had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. During the same period in the previous year, the company posted ($0.03) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company increased its position in Accuray by 13.3% during the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 5,273 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Accuray by 9.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock valued at $181,000 after acquiring an additional 6,583 shares during the last quarter. Renaissance Technologies LLC increased its position in Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after acquiring an additional 7,500 shares during the last quarter. Bank of New York Mellon Corp increased its position in Accuray by 3.3% during the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock valued at $509,000 after acquiring an additional 8,864 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in Accuray by 253,483.3% during the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 15,209 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.